Omeros (OMER) Misses Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
- Oil rises 1% on US-Iran deal doubts; IEA warns of supply glut
Omeros Corporation Reports First Quarter 2016 Financial Results
May 10, 2016 7:20 AM EDT-- Conference Call Today at 9:00 a.m. ET --
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the first quarter of 2016, which include:
1Q 2016 revenues were $7.4 million, an 11% increase over 4Q 2015. Net loss in 1Q was $20.5 million, or $0.54 per share, which included $4.7 million ($0.12 per share) of non-cash... MoreLeonard M. Blum Joins Omeros to Lead Business and Commercial Activities
May 10, 2016 7:05 AM EDTSEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced the hiring of Leonard Blum as chief business and commercial officer. Mr. Blum is leading the companys sales, marketing, commercial strategy and planning, and business development, including for OMIDRIA® (phenylephrine and ketorolac injection) 1% / 0.3% and the companys growing pipeline of development-stage programs.
Mr. Blum brings over 28 years of executive and management experience in... More
